Filing Flows › AdaptHealth (AHCO) › Stock forecast & fair value
AdaptHealth (AHCO) stock forecast and fair value
AdaptHealth (AHCO) trades at $7.33. 7 analysts' median price target is $9.00 (+23%), from $7.00 to $10.00. Across 19 valuation methods the middle fair value is $20.83 (+184%).
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| EV/EBITDA vs peers | −$1.94 | −$0.05 | $7.41 | -101% |
| EV/EBITDA vs peers, weighted | −$5.47 | −$0.49 | $1.23 | -107% |
| EV/EBITDA vs peers, growth-adjusted | −$0.55 | $4.28 | $10.91 | -42% |
| EV/Sales vs peers | $17.04 | $36.45 | $61.69 | +397% |
| EV/Sales vs peers, weighted | $20.61 | $34.95 | $46.91 | +377% |
| EV/Sales vs peers, matched | −$3.59 | $20.83 | $84.69 | +184% |
| EV/Sales vs peers, growth & margin adjusted | $41.13 | $74.54 | $128.38 | +917% |
| Residual income | −$0.28 | −$0.25 | −$0.22 | -103% |
| Analysts' price targets | $7.00 | $8.71 | $10.00 | +19% |
| Path-to-margin DCF | $5.83 | $55.40 | $104.83 | +656% |
AdaptHealth's latest quarter
AdaptHealth, Q3 2026: revenue $746M (+11% year over year), operating margin -20.9%, net loss $153M, operating cash flow $157M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for AHCO stock?
The median of 7 analysts' 12-month targets is $9.00, +23% from $7.33; the range is $7.00 to $10.00. The average rating is strong buy.
What is AdaptHealth's fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between −$0.49 and $74.54, with a middle value of $20.83 against a price of $7.33. Each method's assumptions are on the page.
Does AdaptHealth usually beat earnings estimates?
It beat the consensus EPS estimate in 20% of the quarters on record.
Is AHCO stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.